{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-020539","form_type":"8-K","ticker":"SIGY","cik":"0001642159","company_name":"Sigyn Therapeutics, Inc.","filed_at":"2023-06-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.796547+00:00","generated_at":"2026-06-14T05:01:02.765426+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Sigyn Therapeutics reports conversion of convertible debentures into 1,243,000 common shares","bullets":["On June 2, 2023, $16,500 debenture converted into 33,000 shares at $0.50 per share.","Also on June 2, 2023, $181,500 of other debentures converted into 1,210,000 shares at $0.15 per share.","Outstanding shares increased from 42,981,659 to 44,224,659 as a result of these conversions.","Remaining convertible debentures total $970,200 aggregate principal due through March 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-020539","json":"https://secwatch.observer/filing/0001493152-23-020539.json","markdown":"https://secwatch.observer/filing/0001493152-23-020539.md","text":"https://secwatch.observer/filing/0001493152-23-020539.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1642159/000149315223020539/0001493152-23-020539-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1642159/000149315223020539/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T05:01:02.765426+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}